{"id":27,"date":"2026-05-23T12:53:15","date_gmt":"2026-05-23T12:53:15","guid":{"rendered":"https:\/\/astinovabiolabs.com\/blog\/?p=27"},"modified":"2026-05-23T12:53:15","modified_gmt":"2026-05-23T12:53:15","slug":"synthesis-of-baxdrostat-baxfendy-drug-intelligence-dossier","status":"publish","type":"post","link":"https:\/\/astinovabiolabs.com\/blog\/synthesis-of-baxdrostat-baxfendy-drug-intelligence-dossier\/","title":{"rendered":"Synthesis of Baxdrostat (Baxfendy\u2122) \u2014 Drug Intelligence Dossier"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"537\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-1024x537.png\" alt=\"\" class=\"wp-image-28\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-1024x537.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-300x157.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-768x402.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-1536x805.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image.png 1836w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"2-patent-landscape-exclusivity\">Patent Landscape &amp; Exclusivity<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"21-key-patent-filings\">2.1 Key patent filings<\/h3>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"529\" height=\"1024\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-5-529x1024.png\" alt=\"\" class=\"wp-image-34\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-5-529x1024.png 529w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-5-155x300.png 155w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-5.png 762w\" sizes=\"auto, (max-width: 529px) 100vw, 529px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"3-synthesis-route-of-the-originator\">Synthesis Route of the Originator<\/h2>\n\n\n\n<p>Convergent synthesis disclosed in WO 2014\/135561 (Roche). Eastern fragment: 1-methyl-6-bromo-3,4-dihydroquinolin-2(1H)-one (INT-2) \u2192 pinacolboronate (INT-3, via Pd\/B2pin2 Miyaura). Western fragment: (R)-8-aminotetrahydroisoquinoline scaffold, Boc-protected (INT-5), 4-bromide for coupling. Late-stage convergence: Suzuki C\u2013C coupling at THIQ-C4\/DHQ-C6 (\u2192 INT-7), TFA Boc deprotection (\u2192 INT-8), propionoylation with propionyl chloride \/ Et3N (\u2192 baxdrostat). Chirality-setting step is the key process-IP question; Roche likely uses asymmetric reductive amination or transaminase on the THIQ-C8 ketone (specific route in patent working examples \u2014 not yet disclosed in open primary literature).<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"418\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3-1024x418.png\" alt=\"\" class=\"wp-image-31\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3-1024x418.png 1024w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3-300x122.png 300w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3-768x313.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3-1536x627.png 1536w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-3.png 1760w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"887\" height=\"1024\" src=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-4-887x1024.png\" alt=\"\" class=\"wp-image-32\" srcset=\"https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-4-887x1024.png 887w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-4-260x300.png 260w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-4-768x887.png 768w, https:\/\/astinovabiolabs.com\/blog\/wp-content\/uploads\/2026\/05\/image-4.png 1330w\" sizes=\"auto, (max-width: 887px) 100vw, 887px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"54-key-peer-reviewed-literature\">Key peer-reviewed literature<\/h3>\n\n\n\n<p><em>According to PubMed, the following recent peer-reviewed records are most relevant:<\/em><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Qureshi AJ et al.,\u00a0<em>Cardiovasc Drugs Ther<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1007\/s10557-026-07887-2\">Baxdrostat and Aldosterone Synthase Inhibitors: A New Class for Treatment-resistant Hypertension<\/a>\u00a0(PMID 42126470) \u2014\u00a0<em>Direct baxdrostat review with updated BaxHTN + Bax24 numbers used in \u00a75.2<\/em><\/li>\n\n\n\n<li>Gallo G et al.,\u00a0<em>Eur Heart J Suppl<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suag049\">Aldosterone synthesis inhibitors in resistant hypertension: the BaxHTN trial<\/a>(PMID 42099482) \u2014\u00a0<em>ASI class review centred on BaxHTN<\/em><\/li>\n\n\n\n<li>Cherney DZI et al.,\u00a0<em>Diabetes Obes Metab<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1111\/dom.70836\">Effects of Vicadrostat\/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup Analyses<\/a>\u00a0(PMID 42086479) \u2014\u00a0<em>Competitor (vicadrostat \/ BI 690517) Ph2 CKD subgroup data used in \u00a77.4<\/em><\/li>\n\n\n\n<li>Gill OA et al.,\u00a0<em>Dose Response<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1177\/15593258261449239\">Optimal Dose of Lorundrostat in Uncontrolled Hypertension: A Dose Response Meta-Analysis<\/a>\u00a0(PMID 42130914) \u2014\u00a0<em>Competitor (lorundrostat) meta-analysis used in \u00a77.4<\/em><\/li>\n\n\n\n<li>Schnell O et al.,\u00a0<em>Cardiovasc Diabetol<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1186\/s12933-026-03140-0\">CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum<\/a>\u00a0(PMID 42092956) \u2014\u00a0<em>Highlights baxdrostat (BaxHTN) and finerenone + empagliflozin (CONFIDENCE) \u2014 CKM positioning<\/em><\/li>\n\n\n\n<li>Parisien-La Salle S et al.,\u00a0<em>Endocrinol Metab Clin North Am<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1016\/j.ecl.2025.12.002\">Evaluation and Management of Primary Aldosteronism<\/a>\u00a0(PMID 42067270) \u2014\u00a0<em>Confirms ASIs as new option for PA \u2014 supports \u00a75.2 label-expansion thesis (NCT07007793)<\/em><\/li>\n\n\n\n<li>Todua I et al.,\u00a0<em>Am J Med<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1016\/j.amjmed.2026.05.003\">Management of salt-sensitive hypertension in clinical settings<\/a>\u00a0(PMID 42103091) \u2014\u00a0<em>Salt-sensitive HTN as a target sub-population; ASIs noted<\/em><\/li>\n\n\n\n<li>Mohagaonkar S et al.,\u00a0<em>Br J Pharmacol<\/em>\u00a02026 \u2014\u00a0<a href=\"https:\/\/doi.org\/10.1111\/bph.70502\">Atrial natriuretic peptide counteracts aldosterone secretion by preventing acute angiotensin II-induced&#8230;<\/a>\u00a0(PMID 42116793) \u2014\u00a0<em>Mechanistic background \u2014 ANP\/cGMP\/PDE2A pathway opposing aldosterone<\/em><\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"55-endpoint-landscape-across-phase-3-resistant-htn-trials\">5.5 Endpoint landscape across Phase 3 resistant-HTN trials<\/h3>\n\n\n\n<p>Across 30 Phase-3 resistant-HTN trials analysed (ClinicalTrials.gov v2 MCP): the canonical primary endpoint is change-from-baseline in seated office SBP at week 12. Secondary endpoints centre on DBP, 24-h ABPM, and the proportion achieving SBP &lt;130 mmHg. BaxHTN&#8217;s 2-mg arm (\u221215.7 mmHg absolute \/ \u22129.8 placebo-corrected) and Bax24&#8217;s \u221214.0 mmHg placebo-corrected 24-h ABPM are positioned at the high end of the class.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"81-cmc-manufacturing-risk-profile\">CMC \/ manufacturing risk profile<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>API DMF holder:<\/strong>\u00a0Not yet listed at FDA DMF search (typical filing post-NDA approval); monitor for DMF Type II filing 6\u201312 months post-launch<\/li>\n\n\n\n<li><strong>Drug product CMO:<\/strong>\u00a0Not publicly disclosed; likely AstraZeneca internal Macclesfield (UK) site or contract (AZ has historically split internal\/external for tablet products)<\/li>\n\n\n\n<li><strong>KSM supply:<\/strong>\u00a0Dihydroquinolinone and tetrahydroisoquinoline scaffolds: commodity, Chinese\/Indian CMOs<\/li>\n\n\n\n<li><strong>Critical process risk:<\/strong>\u00a0(1) chirality-setting step on THIQ-C8 (transaminase or chiral hydrogenation) \u2014 IP-protected, hard to second-source; (2) Pd residual control on Suzuki step (\u226410 ppm per ICH Q3D); (3) polymorph control of final API<\/li>\n\n\n\n<li><strong>Estimated API COGs (USD):<\/strong>\u00a0Back-of-envelope at commercial scale:\u00a0<strong>$1,000\u20133,000 \/ kg API<\/strong>\u00a0(4 late-stage steps + 3 steps each fragment, Pd-catalyzed Suzuki, chiral catalyst). At 1\u20132 mg dose,\u00a0<strong>&lt;$0.01 COGs per tablet<\/strong>\u00a0\u2192 wide gross margin vs. expected US list price (likely $5\u201310\/tablet)<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"61-pharmacokinetics-metabolism\">Pharmacokinetics &amp; metabolism<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th class=\"has-text-align-left\" data-align=\"left\">Property<\/th><th class=\"has-text-align-left\" data-align=\"left\">Value<\/th><\/tr><\/thead><tbody><tr><td class=\"has-text-align-left\" data-align=\"left\">Half-life (t\u00bd)<\/td><td class=\"has-text-align-left\" data-align=\"left\">26\u201331 h (supports once-daily dosing)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">Tmax<\/td><td class=\"has-text-align-left\" data-align=\"left\">0.5\u20132 h (rapid absorption)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">Primary metabolism<\/td><td class=\"has-text-align-left\" data-align=\"left\">CYP3A4 (inferred from itraconazole DDI study NCT06357520; itraconazole = potent 3A4 inhibitor)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">PD marker (aldosterone suppression)<\/td><td class=\"has-text-align-left\" data-align=\"left\">Plasma aldosterone reduced 51\u201373% on day 10 of MAD; no meaningful effect on cortisol (selectivity confirmed clinically)<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">Food effect<\/td><td class=\"has-text-align-left\" data-align=\"left\">Minimal expected (no specific food-effect language in BaxHTN protocol); QD oral<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">Hepatic impairment<\/td><td class=\"has-text-align-left\" data-align=\"left\">Likely dose adjustment in moderate\u2013severe (CYP3A4 substrate); specific study pending<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">Renal impairment<\/td><td class=\"has-text-align-left\" data-align=\"left\">Small molecule (MW 363); not dialyzable; expect modest clearance reduction at low eGFR but CKD development program (NCT06268873) ongoing<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">QT\/QTc study<\/td><td class=\"has-text-align-left\" data-align=\"left\">NCT06194032 \u2014 thorough QT\/QTc (Phase 1), negative at therapeutic and supratherapeutic doses<\/td><\/tr><tr><td class=\"has-text-align-left\" data-align=\"left\">\u00b9\u2074C-AME (mass balance)<\/td><td class=\"has-text-align-left\" data-align=\"left\">NCT05961384 \u2014 \u00b9\u2074C-baxdrostat mass balance (completed; full report not yet published)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>DDI \/ interaction flags:<\/strong>&nbsp;&#8211; Strong CYP3A4 inhibitors: Ketoconazole, ritonavir, clarithromycin \u2014 expect dose-reduction \/ contraindication language &#8211; Strong CYP3A4 inducers: Rifampin, phenytoin, carbamazepine, St. John&#8217;s wort \u2014 expect reduced efficacy warning &#8211; Transporter: MATE1 \/ MATE2-K inhibition IC\u2085\u2080 ~1.3\u20132.7 \u00b5M (per Selleck data) \u2014 clinically relevant for metformin renal clearance<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Patent Landscape &amp; Exclusivity 2.1 Key patent filings Synthesis Route of the Originator Convergent synthesis disclosed in WO 2014\/135561 (Roche). Eastern fragment: 1-methyl-6-bromo-3,4-dihydroquinolin-2(1H)-one (INT-2) \u2192 pinacolboronate (INT-3, via Pd\/B2pin2 Miyaura). Western fragment: (R)-8-aminotetrahydroisoquinoline scaffold, Boc-protected (INT-5), 4-bromide for&hellip;<\/p>\n","protected":false},"author":1,"featured_media":33,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-27","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"_links":{"self":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/27","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/comments?post=27"}],"version-history":[{"count":1,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/27\/revisions"}],"predecessor-version":[{"id":35,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/posts\/27\/revisions\/35"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media\/33"}],"wp:attachment":[{"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/media?parent=27"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/categories?post=27"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/astinovabiolabs.com\/blog\/wp-json\/wp\/v2\/tags?post=27"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}